Arcturus Therapeutics (ARCT) announced the initiation of the company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus.
Education
About Us
Working with TipRanks
Follow Us
1